Sickle Cell Anemia Testing and Screening Market Overview
The global sickle cell anemia testing and screening marketsize is poised for significant growth, with the market size expected to increase from USD 1.7 billion in 2025 to approximately USD 3.6 billion by 2033, expanding at a robust CAGR of 10 % during the forecast period. This market encompasses a range of testing methods, including hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), point-of-care tests, and genetic testing, each playing a vital role in early detection and management of sickle cell anemia, a genetic blood disorder characterized by abnormal hemoglobin production
The market for sickle cell testing and screening is expanding rapidly as governments and health organizations strengthen newborn screening initiatives and as technology lowers the barriers to access. According to various industry analyses, the market is estimated to be worth several hundred million USD in 2025, with a projected CAGR in the range of 10–12% during the forecast period. This strong growth reflects not only the rising disease burden but also improvements in healthcare infrastructure and increased awareness among both patients and providers.
Government-Led Newborn Screening Programs Newborn screening is the cornerstone of early detection. Countries such as the United States, the United Kingdom, India, and several African nations have made significant progress in incorporating sickle cell testing into mandatory newborn panels. These policies are fueling steady demand for screening assays and instruments.
Rising Global Awareness and Advocacy Global campaigns by the WHO, UN agencies, and patient advocacy groups are improving awareness about the benefits of early testing. Public-health campaigns encourage parents to test newborns and prospective parents to consider carrier screening.
Advances in Point-of-Care (POC) Diagnostics POC devices — particularly affordable lateral-flow rapid tests — are revolutionizing screening in low-resource settings. These devices enable quick results in community clinics and outreach programs without sophisticated laboratory infrastructure.
Expansion of Molecular and Genetic Testing While conventional methods such as HPLC (High-Performance Liquid Chromatography) and IEF (Isoelectric Focusing) remain the mainstay for initial detection, molecular testing (PCR-based genotyping and next-generation sequencing) is gaining momentum. It supports prenatal screening, carrier detection, and precision medicine initiatives.
North America & Europe: Mature markets with well-established newborn screening frameworks.
Asia-Pacific: Rapidly expanding programs, especially in India and Southeast Asia.
Africa & Middle East: High-burden regions benefiting from donor-funded programs and adoption of low-cost POC devices.
Latin America: Gradual integration of sickle cell testing in national screening strategies.
Competitive Landscape
The market features a mix of established diagnostics companies and specialized innovators:
Bio-Rad Laboratories, PerkinElmer, and similar companies lead in laboratory-based systems such as HPLC and electrophoresis.
BioMedomics and other startups have pioneered low-cost rapid POC tests, which are particularly important for resource-limited regions.
Emerging genetic-testing providers and laboratory service networks are expanding offerings for prenatal and carrier screening.
Strategic collaborations between manufacturers, governments, and NGOs are proving essential to expand access to reliable and affordable testing.
Challenges
Despite the momentum, the market faces several hurdles:
Infrastructure Limitations: Many rural and underserved regions still lack basic laboratory capacity, trained personnel, and logistics for sample transport.
Cost Barriers: Although POC devices have reduced costs, confirmatory molecular tests can be expensive without government support or insurance coverage.
Quality Control: Decentralized screening programs must maintain high standards for accuracy, requiring robust training and quality-assurance systems.
Opportunities Ahead
Integrated Screening Networks: Linking POC tests with centralized labs for confirmatory testing can ensure both broad access and diagnostic accuracy.
Digital Health Solutions: Mobile-based reporting and data management platforms can streamline program monitoring and improve patient follow-up.
Expansion of Prenatal and Carrier Testing: As sequencing technologies become more affordable, these segments are likely to show significant growth.
Public-Private Partnerships: Government support combined with private sector expertise can accelerate scale-up of national screening programs.
Future Outlook
The next decade is expected to witness significant transformation in how SCA is detected and managed:
The combination of POC screening and molecular confirmation will become the gold standard in many regions.
Bundled newborn screening panels will continue to drive routine early-life testing in developed markets.
Education and advocacy will remain vital to ensure that at-risk populations seek testing and follow-up care.
By leveraging innovation and forging strategic alliances, diagnostic companies can play a pivotal role in addressing the global burden of sickle cell disease.
We are a purpose-driven market research and consulting company passionate about turning data into direction. Founded in 2023, we bring together researchers, strategists, and data scientists who believe that intelligence isn’t just about numbers, it’s about insight that sparks progress.
We cater to a wide range of industries by delivering customized solutions, strategic insights, and innovative support that help organizations grow, adapt, and lead in their respective sectors. Here’s a brief overview of key industries we work with
Downloader
Free FTP
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
